Description

Description: The VI-PL2 monoclonal antibody reacts with human CD61, also known as integrin beta 3 and GPIIIa. CD61 is a 90-110kDa member of the beta integrin family expressed by a wide variety of cells, including leukocytes, platelets, endothelial and smooth muscle cells. CD61 binds non-covalently with the alpha integrins CD41 and CD51, to form the alpha IIb beta3 (CD41/CD61) and alpha v beta3 (CD51/CD61) complexes. These alpha beta heterodimers are capable of mediating a variety of cellular responses including adhesion, trafficking, proliferaton and differentiation. The CD41/CD61 integrin has been shown to be involved in platelet aggregation, and binds to fibrinogen, von Willebrand Factor (vWF) and fibronectin. The CD51/CD61 integrin binds to matrix proteins including vitronectin, fibronectin, vWF and fibrinogen, and has been shown to have a strong role in modulating the migration and survival of angiogenic endothelial cells.This VI-PL2 antibody has also been shown to crossreact with canine and several non-human primate species, including baboon, rhesus, and cynomologus monkey.Applications Reported: This VI-PL2 antibody has been reported for use in flow cytometric analysis, immunoprecipitation, immunohistochemical staining, and functional assays.Applications Tested: This VI-PL2 antibody has been tested by flow cytometric analysis of human peripheral blood platelets. This can be used at less than or equal to 0.125 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.Purity: Greater than 90%, as determined by SDS-PAGE.Aggregation: Less than 10%, as determined by HPLC.Filtration: 0.2μm post-manufacturing filtered.